# MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM

> **NCT03072407** · PHASE1 · COMPLETED · sponsor: **PegBio Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** PB-119 injection
- **BIOLOGICAL:** PB-119 injection placebo

## Key facts

- **NCT ID:** NCT03072407
- **Lead sponsor:** PegBio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-24
- **Primary completion:** 2016-11-02
- **Final completion:** 2016-11-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03072407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03072407, "MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03072407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*